Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

EQT INFRASTRUCTURE VI, THROUGH OTELLO BIDCO AB, PUBLISHES SUPPLEMENT TO THE OFFER DOCUMENT FOR THE RECOMMENDED PUBLIC OFFER TO THE SHAREHOLDERS OF OX2 AB (PUBL)

This announcement is not an offer, whether directly or indirectly, in Australia, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in

Grant of incentive warrants to Employees, CEO and the Board of Directors

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant a new incentive warrants to existing and new employees, to the CEO and the Board of Directors. The reason for the new warrant program is to retain and incentivize the employees, the Board of Directors and the CEO by offering a long-term ownership engagement, which will contribute to an alignment of interests between the warrant holders and the shareholders and promote long-term commitment to the Company’s development.Background and final termsOn 26 July 2024 it was decided to grant 250,000 warrants

CS MEDICA A/S Evaluates Pre-IPO Share Distribution for CANNORDIC Stock Spin-off

CS MEDICA Aims to Strengthen Shareholder Bonds with Pre-IPO Share Distribution for CANNORDIC in GermanyCS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD, announced on June 10, 2024, its plans to spin off stocks and list its subsidiary CANNORDIC A/S on the German Stock Market (Intention to Float). Today, the company announces its evaluation of the possibility of distributing CANNORDIC shares to existing CS MEDICA shareholders ahead of the planned initial public offering (IPO) in 2024, approved at the

Borr Drilling Limited – Contracting Update

Borr Drilling Limited (NYSE and OSE: “BORR”) is pleased to announce new contract commitments for three of its premium jack-up rigs, the “Arabia I”, the “Gunnlod” and the “Norve”.  These commitments cover a total of 1,779 days and $332 million in contract revenue, including mobilization and demobilization compensation.  The “Arabia I” which had its work scope suspended earlier this year in Saudi Arabia has secured a new long-term contract in Brazil. The contract period is 4 years firm plus a 4 years unpriced option. This contract is expected to commence in Q1 2025 in cooperation with an

CORRECTION: ACQUISITION OF OWN SHARES OF Alexandria Group Oyj

CORRECTION: ACQUISITION OF OWN SHARES OF Alexandria Group OyjALEXANDRIA GROUP OYJ Company Announcement 26.7.2024 at 15:00 EET   Correction: Starting from 19 June 2024, the company announcement of Alexandria Group Oyj (the company) relating to the acquisition of own shares of the company have contained incorrect information on the number of own shares held by the company. The correct numbers have been 152 541 shares lower than the previously announced numbers. The correct numbers of own shares held by the company are as follows:   22,889 shares                   19.06.2024

Should You Water Grass While It’s Sunny? - Expert Advice

Watering the lawn is a fundamental part of keeping your garden green and healthy. But with so many conflicting opinions floating around, it can be confusing to know exactly when to water your grass. A common question many homeowners ask is: should you water your grass while it's sunny?   [A sprinkler spraying water on grass Description automatically generated]   Here, gardening expert Fiona Jenkins at MyJobQuote.co.uk  delves into the world of lawn care and explores the pros and cons of watering during sunny spells, along with expert advice to

DOF GROUP ASA - Extraordinary General Meeting

Austevoll, 26 July 2024: Reference is made to the stock exchange announcement made by DOF Group ASA (the "Company", OSE ticker code "DOFG") on 2 July 2024 regarding an agreement to acquire Maersk Supply Service A/S (the "Transaction"), and on 5 July 2024 regarding an extraordinary general meeting to be held on 26 July 2024 (the "EGM"). The EGM was held today as a digital meeting with online participation. All proposals on the agenda were adopted, cf. the notice of the EGM that was published on 5 July 2024. The EGM elected two new board members: Erik Bergöö as the vice chairperson of the

Eisai will seek re-examination of CHMP opinion för lecanemab

Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will request re-examination of the Committee for Medicinal Products for Human Use (CHMP’s) negative opinion posted today on the Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease in the EU.“We are surprised and very disappointed by the CHMP’s opinion posted today. Foremost  the negative opinion adopted by the CHMP is sad for all patients, caregivers and healthcare professionals in the EU who will now have to wait longer for a

CHMP has adopted a negative opinion on lecanemab for the EU

Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has today communicated that it has adopted a negative opinion on BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai’s Marketing Authorization Approval (MAA) for lecanemab as treatment for Alzheimer’s disease. BioArctic is currently consulting Eisai regarding forthcoming actions. A further update will be communicated later todayLecanemab is already approved in the United States, Japan, China, South Korea, Hong Kong, and Israel and is being marketed in

Ellos Group announces that it has received an acceleration notice in respect of its outstanding bonds and contemplates a standstill agreement with major bondholders

Press release, Borås, 26 July 2024 On 14 July 2024, Ellos Group AB (publ) (“Ellos Group” or the “Company”) announced that the Company had initiated a constructive dialogue with certain holders under the Company’s outstanding SEK 1,500,000,000 senior secured bonds due 25 July 2024 (the “Senior Bonds”) and SEK 250,000,000 super senior secured bonds due 9 February 2025 (jointly, the “Existing Bonds”) to find a long-term refinancing solution for the Existing Bonds and to strengthen Ellos Group’s capital structure. In connection with the Company’s inability to repay the Senior Bonds at

$5.5 Million Raised in the United States to Preserve Finnish Cultural Heritage

Finnish cultural heritage in the United States faced an existential threat, but donors stepped in. Now, over $5.5 million has been raised to preserve the unique Finnish-America history.Finlandia Foundation National (FFN), a non-profit organization dedicated to preserving Finnish cultural heritage in the US, has announced the results of the "Saving Finland in America" campaign. Over 900 individual donors, families, organizations, and nonprofit foundations across Finnish-America have donated a record-breaking $5.5 million to ensure the preservation of the unique Finnish-American cultural

Cell Impact and F.C.C. take their collaboration to the next level

The collaboration between Cell Impact and Japanese F.C.C. continues to deepen. Recently, the two companies undertook a joint effort to position Cell Impact Forming™ in China.In China, Cell Impact and F.C.C. visited several customers and prospects to display the benefits of Cell Impact Forming and the opportunities for large-scale production in Asia that the collaboration with F.C.C. offers. Some of the companies visited was Nowogen, Anchor, and Horizon Fuel Cell Technologies, of which Nowogen is one of Cell Impact’s early customers. “This visit is a great example of how the deepened

Post Stabilisation Notice

DZ Bank AG: Post-Stabilisation Notice Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. DZ BANK AG (contact: Ralph Ockert; telephone: +49 69 7447 7051) herebygives notice that no stabilisation (within the meaning of Article 3.2 (d) of the Market Abuse Regulation (EU Regulation 596/2014) was undertaken by the Stabilising Managers named below in relation to the offer of the following securities. The security to be stabilised: Issuer:                           European Union (EU)

Post -Stabilisation Notice

DZ Bank AG: Post-Stabilisation Notice Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. DZ BANK AG (contact: Ralph Ockert; telephone: +49 69 7447 7051) herebygives notice that no stabilisation (within the meaning of Article 3.2 (d) of the Market Abuse Regulation (EU Regulation 596/2014) was undertaken by the Stabilising Managers named below in relation to the offer of the following securities. The security to be stabilised: Issuer:                           European Union (EU)

Correction of previous press release

The press release that was published earlier today on 26 July 2024 at 08:00 CET has been updated with the right cash flow figures for Vehicles and Services as it previously showed the cash flow figures for Scania Group. The rest of the press release is unchanged.Strong financial performance in the second quarter, with significant growth in sales and earnings. • Scania Group net sales grew by 9 percent to SEK 55.4 billion (51.0) • Adjusted operating income reached SEK 8.0 billion (7.0) and adjusted operating margin was 14.5 percent (13.6) • Vehicle deliveries increased by 8 percent

CasinoRank Network Unveils Major Menu Redesign Across Its Websites

Stockholm, Sweden, 26 July 2024 – CasinoRank Network is thrilled to announce a major redesign of the menu across its websites. This significant update aims to enhance technological progression, SEO optimization, and automation improvements, providing users with a more seamless and intuitive browsing experience.After months of meticulous planning and development, the CasinoRank team has launched a revamped menu system that caters to the unique content of each specific website within the network. For example, OnlineCasinoRank now features dedicated sections for table game reviews, while

Dampskibsselskabet NORDEN A/S – final weekly report on share buy-back

ANNOUNCEMENT NO. 169 – 26 JULY 2024   On 25 April 2024, NORDEN initiated a share buy-back programme in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052, (Safe Harbour regulation). The share buy-back programme runs from 26 April 2024 up to and including no later than 1 August 2024. For details, please see announcement no. 96 of 25 April 2024.   Under the share buy-back programme, NORDEN will purchase shares for up to a total of USD 21 million (approximately DKK 145 million).

Arctic Bioscience – Mandatory notification of trade

Nils Erik Bjørkedal, a person closely associated with a person discharging managerial responsibility in Arctic Bioscience, has bought 10.000 shares in Arctic Bioscience at an average price of NOK 10,42 per share. Following the transaction, Nils Erik Bjørkedal holds 10.000 shares in Arctic Bioscience.Nils Erik Bjørkedal is closely associated with the Quality Manager in Arctic Bioscience, Jannicke Bjørkedal. Please refer to the attached notification of trading for further details.  This information is subject to the disclosure requirements pursuant to Regulation EU 596/2014 (MAR)

CS MEDICA Leverages Strategic Partnerships for CANNASEN® Brand Launch in APAC and MENA

Launching 36,000 Units to Test Market Fit and Accelerate Market Penetration at a value of €419,000CS MEDICA announces an advancement in its expansion strategy with the upcoming launch of CANNASEN® in the Asia-Pacific (APAC) and Middle East/North Africa (MENA) regions. This launch utilizes strong partnerships and a Minimum Viable Product (MVP) approach to establish the CANNASEN® brand. CS MEDICA will distribute 36,000 units of CANNASEN® to APAC and MENA at a value of €419,000 starting August 2024. This initiative aims to gather consumer insights to perfect product alignment and readiness

Sleep Cycle interim report April – June 2024: Laying the foundation for continued sustainable and profitable growth

Gothenburg, Sweden – 26 July, 2024The second quarter in summary (April-June 2024) · Net sales totaled tSEK 65,442 (57,952) and increased by 12.9% (11.0%). Currency-adjusted net sales growth amounted to 10.5% (1.1%). · Operating profit amounted to tSEK 20,964 (12,732), with an operating margin of 32.0% (22.0%). · Adjusted operating profit totaled tSEK 20,964 (17,265) and adjusted operating margin was 32.0% (29.8%). · The total number of paying subscribers at end of period was 898k (877k). · ARPU in the quarter amounted to SEK 282 (263). Currency adjusted ARPU was SEK 277.

SAS files monthly operating reports with U.S. court and announces certain financial information for the Group

SAS AB (“SAS” or the “Company”) and each of its subsidiaries that are subject to the voluntary chapter 11 process in the U.S. will shortly file monthly operating reports, containing certain financial information for the period of November 1, 2023 to June 30, 2024 with the U.S. Bankruptcy Court for the Southern District of New York (the “Court”). All SAS companies that are subject to the voluntary chapter 11 process are each required to file operating reports with the Court on a monthly basis. The financial information contained in the monthly operating reports includes items such as cash

Terrafame's operating result for January–June 2024 improved year-on-year

The financial information presented about Terrafame Ltd in this media release consists of unaudited IFRS figures. The figures in brackets refer to the corresponding period in the previous year unless otherwise stated. April−June 2024 in brief: · Net sales were EUR 116.0 (91.4) million, representing an increase of 21.2% year-on-year. · Net sales from the battery chemicals business decreased to EUR 29.4 (32.1) million, or 25.3% (35.1) of the company’s total net sales. Net sales were negatively affected by lower production and delivery volumes as well as a decrease in the market

There are no items matching the current filter
There are no more items matching the current filter
Back to top